Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma

Cancer

Volumn 95, Issue 1, 2002, Pages 127-134

  Eton, Omar ^a   Rosenblum, Michael G ^b   Legha, Sewa S ^c   Zhang, Wehei ^b   East, Mary Jo ^a   Bedikian, Agop ^a   Papadopoulos, Nicholas ^a   Buzaid, Antonio ^d   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Biochemotherapy; Clinical trial; Cytokine; Interleukin 2; Metastatic melanoma; Pharmacokinetics

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; FEMALE; FLUID INTAKE; FLUID RETENTION; HEADACHE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UREMIA; VISUAL HALLUCINATION;

ADULT; AGED; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0036645369     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10631     Document Type: Article

References (19)

1. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
2. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: A Phase Ib study
3. Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review
4. Evaluation of interleukin-2 administered as continuous infusion in metastatic melanoma
5. Results of interleukin2-based treatment in advanced melanoma: A case recordbased analysis of 631 patients
6. Efficacy of interleukin-2 in the treatment of metastatic melanoma. Systematic review and meta-analysis
7. Phase III randomized trial of cisplatin, vinblastine, dacarbazine plus interleukin-2 and interferon-alpha-2B versus CVD in patients with metastatic melanoma
8. The role of interleukin-2 in the management of Stage IV melanoma: The EORTC melanoma cooperative group program
9. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts
10. Regulation of local host-mediated anti-tumor mechanisms by cytokines: Direct and indirect effects on leukocyte recruitment and angiogenesis
11. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma
12. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
13. Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration
14. Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer
15. Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2
16. Chemotherapy and cytokine-based immunotherapy for high-risk and metastatic melanoma
17. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two Phase II cytokine working group trials
18. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M. D. Anderson Cancer Center experience